Fructose intake, serum uric acid, and cardiometabolic disorders: A critical review

Nutrients

Volumn 9, Issue 4, 2017, Pages

  Caliceti, Cristiana ^a,b   Calabria, Donato ^a   Roda, Aldo ^a,b   Cicero, Arrigo F G ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b NATIONAL INSTITUTE OF BIOSTRUCTURES AND BIOSYSTEMS   (Italy)

Author keywords

Cardiometabolic disorders; Epidemiology; Fructose; Pathophysiology; Uric acid; Xanthine oxidase

Indexed keywords

ABC TRANSPORTER; ADENOSINE MONOPHOSPHATE DEAMINASE; ADENOSINE TRIPHOSPHATE CITRATE SYNTHASE; ALLANTOIN; BENZBROMARONE; BREAST CANCER RESISTANCE PROTEIN; DIHYDROXYACETONE PHOSPHATE; FATTY ACID SYNTHASE; FRUCTOKINASE; FRUCTOSE 1 PHOSPHATE; GLUCOSE TRANSPORTER; HEME OXYGENASE 1; HYPOXANTHINE PHOSPHORIBOSYLTRANSFERASE; LOSARTAN; MONOCYTE CHEMOTACTIC PROTEIN 1; PROBENECID; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; RIBOSEPHOSPHATE PYROPHOSPHOKINASE; SODIUM PHOSPHATE COTRANSPORTER 1; SULFINPYRAZONE; SUPEROXIDE DISMUTASE; TUMOR NECROSIS FACTOR; UNINDEXED DRUG; URATE OXIDASE; URATE TRANSPORTER; URIC ACID; VASCULAR CELL ADHESION MOLECULE 1; XANTHINE DEHYDROGENASE; XANTHINE OXIDASE; FRUCTOSE;

ARTERIAL STIFFNESS; ATHEROSCLEROTIC PLAQUE; CARBOHYDRATE INTAKE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAROTID ARTERY OBSTRUCTION; COGNITIVE DEFECT; FRUCTOSE INTAKE; FRUCTOSE METABOLISM; GENE MUTATION; HEART FAILURE; HUMAN; HYPERTENSION; HYPERURICEMIA; INSULIN RESISTANCE; LIPID PEROXIDATION; LIPID STORAGE; LIPOGENESIS; METABOLIC DISORDER; OBESITY; OXIDATIVE STRESS; PURINE METABOLISM; REVIEW; URIC ACID BLOOD LEVEL; BLOOD; CARDIOVASCULAR DISEASES; DIET; FEEDING BEHAVIOR; FEMALE; MALE; METABOLIC SYNDROME X;

CARDIOVASCULAR DISEASES; DIET; FEEDING BEHAVIOR; FEMALE; FRUCTOSE; HUMANS; HYPERURICEMIA; MALE; METABOLIC SYNDROME X; URIC ACID;

EID: 85018495509     PISSN: None     EISSN: 20726643     Source Type: Journal    
DOI: 10.3390/nu9040395     Document Type: Review

References (123)

1. Zamudio-Cuevas, Y.; Hernandez-Diaz, C.; Pineda, C.; Reginato, A.M.; Cerna-Cortes, J.F.; Ventura-Rios, L.; Lopez-Reyes, A. Molecular basis of oxidative stress in gouty arthropathy. Clin. Rheumatol. 2015, 34, 1667–1672. [CrossRef] [PubMed]
2. Stack, A.G.; Hanley, A.; Casserly, L.F.; Cronin, C.J.; Abdalla, A.A.; Kiernan, T.J.; Murthy, B.V.; Hegarty, A.; Hannigan, A.; Nguyen, H.T. Independent and conjoint associations of gout and hyperuricaemia with total and cardiovascular mortality. QJM 2013, 106, 647–658. [CrossRef] [PubMed]
3. Sui, X.; Church, T.S.; Meriwether, R.A.; Lobelo, F.; Blair, S.N. Uric acid and the development of metabolic syndrome in women and men. Metabolism 2008, 57, 845–852. [CrossRef] [PubMed]
4. Nakagawa, T.; Hu, H.; Zharikov, S.; Tuttle, K.R.; Short, R.A.; Glushakova, O.; Ouyang, X.; Feig, D.I.; Block, E.R.; Herrera-Acosta, J.; et al. A causal role for uric acid in fructose-induced metabolic syndrome. Am. J. Physiol. Renal. Physiol. 2006, 290, F625–F631. [CrossRef] [PubMed]
5. Gersch, M.S.; Mu, W.; Cirillo, P.; Reungjui, S.; Zhang, L.; Roncal, C.; Sautin, Y.Y.; Johnson, R.J.; Nakagawa, T. Fructose, but not dextrose, accelerates the progression of chronic kidney disease. Am. J. Physiol. Renal. Physiol. 2007, 293, F1256–F1261. [CrossRef] [PubMed]
6. Johnson, R.J.; Segal, M.S.; Sautin, Y.; Nakagawa, T.; Feig, D.I.; Kang, D.H.; Gersch, M.S.; Benner, S.; Sanchez-Lozada, L.G. Potential role of sugar (fructose) in the epidemic of hypertension, obesity and the metabolic syndrome, diabetes, kidney disease, and cardiovascular disease. Am. J. Clin. Nutr. 2007, 86, 899–906. [PubMed]
7. Johnson, R.J.; Titte, S.; Cade, J.R.; Rideout, B.A.; Oliver, W.J. Uric acid, evolution and primitive cultures. Semin. Nephrol. 2005, 25, 3–8. [CrossRef] [PubMed]
8. Borghi, C. The role of uric acid in the development of cardiovascular disease. Curr. Med. Res. Opin. 2015, 31 (Suppl. S2), 1–2. [CrossRef] [PubMed]
9. Iwama, M.; Kondo, Y.; Shimokado, K.; Maruyama, N.; Ishigami, A. Uric acid levels in tissues and plasma of mice during aging. Biol. Pharm. Bull. 2012, 35, 1367–1370. [CrossRef] [PubMed]
10. Johnson, R.J.; Andrews, P.; Benner, S.A.; Oliver, W.; Theodore, E. Woodward award. The evolution of obesity: Insights from the mid-Miocene. Trans. Am. Clin. Climatol. Assoc. 2010, 121, 295–305. [PubMed]
11. Johnson, R.J.; Sautin, Y.Y.; Oliver, W.J.; Roncal, C.; Mu, W.; Gabriela Sanchez-Lozada, L.; Rodriguez-Iturbe, B.; Nakagawa, T.; Benner, S.A. Lessons from comparative physiology: Could uric acid represent a physiologic alarm signal gone awry in western society? J. Comp. Physiol. B 2009, 179, 67–76. [CrossRef] [PubMed]
12. Higgins, P.; Dawson, J.; Lees, K.R.; McArthur, K.; Quinn, T.J.; Walters, M.R. Xanthine oxidase inhibition for the treatment of cardiovascular disease: A systematic review and meta-analysis. Cardiovasc. Ther. 2012, 30, 217–226. [CrossRef] [PubMed]
13. Sorensen, L.B. Mechanism of excessive purine biosynthesis in hypoxanthine-guanine phosphoribosyltransferase deficiency. J. Clin. Investig. 1970, 49, 968–978. [CrossRef] [PubMed]
14. Nishino, T.; Okamoto, K.; Eger, B.T.; Pai, E.F.; Nishino, T. Mammalian xanthine oxidoreductase—Mechanism of transition from xanthine dehydrogenase to xanthine oxidase. FEBS J. 2008, 275, 3278–3289. [CrossRef] [PubMed]
15. Pritsos, C.A. Cellular distribution, metabolism and regulation of the xanthine oxidoreductase enzyme system. Chem. Biol. Interact. 2000, 129, 195–208. [CrossRef]
16. Vorbach, C.; Harrison, R.; Capecchi, M.R. Xanthine oxidoreductase is central to the evolution and function of the innate immune system. Trends Immunol. 2003, 24, 512–517. [CrossRef]
17. Friedl, H.P.; Till, G.O.; Ryan, U.S.; Ward, P.A. Mediator-induced activation of xanthine oxidase in endothelial cells. FASEB J. 1989, 3, 2512–2518. [PubMed]
18. Doehner, W.; Schoene, N.; Rauchhaus, M.; Leyva-Leon, F.; Pavitt, D.V.; Reaveley, D.A.; Schuler, G.; Coats, A.J.; Anker, S.D.; Hambrecht, R. Effects of xanthine oxidase inhibition with allopurinol on endothelial function and peripheral blood flow in hyperuricemic patients with chronic heart failure: Results from 2 placebo-controlled studies. Circulation 2002, 105, 2619–2624. [CrossRef] [PubMed]
19. Perez-Ruiz, F.; Calabozo, M.; Erauskin, G.G.; Ruibal, A.; Herrero-Beites, A.M. Renal underexcretion of uric acid is present in patients with apparent high urinary uric acid output. Arthritis Rheum. 2002, 47, 610–613. [CrossRef] [PubMed]
20. Anzai, N.; Ichida, K.; Jutabha, P.; Kimura, T.; Babu, E.; Jin, C.J.; Srivastava, S.; Kitamura, K.; Hisatome, I.; Endou, H.; et al. Plasma urate level is directly regulated by a voltage-driven urate efflux transporter URATv1 (SLC2A9) in humans. J. Biol. Chem. 2008, 283, 26834–26838. [CrossRef] [PubMed]
21. Enomoto, A.; Kimura, H.; Chairoungdua, A.; Shigeta, Y.; Jutabha, P.; Cha, S.H.; Hosoyamada, M.; Takeda, M.; Sekine, T.; Igarashi, T.; et al. Molecular identification of a renal urate anion exchanger that regulates blood urate levels. Nature 2002, 417, 447–452. [CrossRef] [PubMed]
22. Iharada, M.; Miyaji, T.; Fujimoto, T.; Hiasa, M.; Anzai, N.; Omote, H.; Moriyama, Y. Type 1 sodium-dependent phosphate transporter (SLC17A1 Protein) is a Cl(-)-dependent urate exporter. J. Biol. Chem. 2010, 285, 26107–26113. [CrossRef] [PubMed]
23. Uchino, H.; Tamai, I.; Yamashita, K.; Minemoto, Y.; Sai, Y.; Yabuuchi, H.; Miyamoto, K.; Takeda, E.; Tsuji, A. p-Aminohippuric acid transport at renal apical membrane mediated by human inorganic phosphate transporter NPT1. Biochem. Biophys. Res. Commun. 2000, 270, 254–259. [CrossRef] [PubMed]
24. Richette, P.; Bardin, T. Gout. Lancet 2010, 375, 318–328. [CrossRef]
25. Hosomi, A.; Nakanishi, T.; Fujita, T.; Tamai, I. Extra-renal elimination of uric acid via intestinal efflux transporter BCRP/ABCG2. PLoS ONE 2012, 7, e30456. [CrossRef] [PubMed]
26. Ichida, K.; Matsuo, H.; Takada, T.; Nakayama, A.; Murakami, K.; Shimizu, T.; Yamanashi, Y.; Kasuga, H.; Nakashima, H.; Nakamura, T.; et al. Decreased extra-renal urate excretion is a common cause of hyperuricemia. Nat. Commun. 2012, 3, 764. [CrossRef] [PubMed]
27. Woodward, O.M.; Kottgen, A.; Coresh, J.; Boerwinkle, E.; Guggino, W.B.; Kottgen, M. Identification of a urate transporter, ABCG2, with a common functional polymorphism causing gout. Proc. Natl. Acad. Sci. USA 2009, 106, 10338–10342. [CrossRef] [PubMed]
28. Litman, T.; Jensen, U.; Hansen, A.; Covitz, K.M.; Zhan, Z.; Fetsch, P.; Abati, A.; Hansen, P.R.; Horn, T.; Skovsgaard, T.; et al. Use of peptide antibodies to probe for the mitoxantrone resistance-associated protein MXR/BCRP/ABCP/ABCG2. Biochim. Biophys. Acta 2002, 1565, 6–16. [CrossRef]
29. Kage, K.; Tsukahara, S.; Sugiyama, T.; Asada, S.; Ishikawa, E.; Tsuruo, T.; Sugimoto, Y. Dominant-negative inhibition of breast cancer resistance protein as drug efflux pump through the inhibition of S-S dependent homodimerization. Int. J. Cancer 2002, 97, 626–630. [CrossRef] [PubMed]
30. Takada, T.; Suzuki, H.; Sugiyama, Y. Characterization of polarized expression of point- or deletion-mutated human BCRP/ABCG2 in LLC-PK1 cells. Pharm. Res. 2005, 22, 458–464. [CrossRef] [PubMed]
31. Ogura, J.; Kuwayama, K.; Sasaki, S.; Kaneko, C.; Koizumi, T.; Yabe, K.; Tsujimoto, T.; Takeno, R.; Takaya, A.; Kobayashi, M.; et al. Reactive oxygen species derived from xanthine oxidase interrupt dimerization of breast cancer resistance protein, resulting in suppression of uric acid excretion to the intestinal lumen. Biochem. Pharmacol. 2015, 97, 89–98. [CrossRef] [PubMed]
32. Ogura, J.; Kuwayama, K.; Takaya, A.; Terada, Y.; Tsujimoto, T.; Koizumi, T.; Maruyama, H.; Fujikawa, A.; Takahashi, N.; Kobayashi, M.; et al. Intestinal ischemia-reperfusion increases efflux for uric acid via paracellular route in the intestine, but decreases that via transcellular route mediated by BCRP. J. Pharm. Pharm. Sci. 2012, 15, 295–304. [CrossRef] [PubMed]
33. Hediger, M.A.; Johnson, R.J.; Miyazaki, H.; Endou, H. Molecular physiology of urate transport. Physiology (Bethesda) 2005, 20, 125–133. [CrossRef] [PubMed]
34. Wu, X.W.; Muzny, D.M.; Lee, C.C.; Caskey, C.T. Two independent mutational events in the loss of urate oxidase during hominoid evolution. J. Mol. Evol. 1992, 34, 78–84. [CrossRef] [PubMed]
35. Ames, B.N.; Cathcart, R.; Schwiers, E.; Hochstein, P. Uric acid provides an antioxidant defense in humans against oxidant- and radical-caused aging and cancer: A hypothesis. Proc. Natl. Acad. Sci. USA 1981, 78, 6858–6862. [CrossRef] [PubMed]
36. Lanaspa, M.A.; Sanchez-Lozada, L.G.; Choi, Y.J.; Cicerchi, C.; Kanbay, M.; Roncal-Jimenez, C.A.; Ishimoto, T.; Li, N.; Marek, G.; Duranay, M.; et al. Uric acid induces hepatic steatosis by generation of mitochondrial oxidative stress: Potential role in fructose-dependent and -independent fatty liver. J. Biol. Chem. 2012, 287, 40732–40744. [CrossRef] [PubMed]
37. Choi, H.K.; Gao, X.; Curhan, G. Vitamin C intake and the risk of gout in men: A prospective study. Arch. Intern. Med. 2009, 169, 502–507. [CrossRef] [PubMed]
38. Berger, L.; Gerson, C.D.; Yu, T.F. The effect of ascorbic acid on uric acid excretion with a commentary on the renal handling of ascorbic acid. Am. J. Med. 1977, 62, 71–76. [CrossRef]
39. Stein, H.B.; Hasan, A.; Fox, I.H. Ascorbic acid-induced uricosuria. A consequency of megavitamin therapy. Ann. Intern. Med. 1976, 84, 385–388. [CrossRef] [PubMed]
40. Choi, Y.J.; Shin, H.S.; Choi, H.S.; Park, J.W.; Jo, I.; Oh, E.S.; Lee, K.Y.; Lee, B.H.; Johnson, R.J.; Kang, D.H. Uric acid induces fat accumulation via generation of endoplasmic reticulum stress and SREBP-1c activation in hepatocytes. Lab. Investig. 2014, 94, 1114–1125. [CrossRef] [PubMed]
41. Bedir, A.; Topbas, M.; Tanyeri, F.; Alvur, M.; Arik, N. Leptin might be a regulator of serum uric acid concentrations in humans. Jpn. Heart J. 2003, 44, 527–536. [CrossRef] [PubMed]
42. Cheung, K.J.; Tzameli, I.; Pissios, P.; Rovira, I.; Gavrilova, O.; Ohtsubo, T.; Chen, Z.; Finkel, T.; Flier, J.S.; Friedman, J.M. Xanthine oxidoreductase is a regulator of adipogenesis and PPARgamma activity. Cell Metab. 2007, 5, 115–128. [CrossRef] [PubMed]
43. Fruehwald-Schultes, B.; Peters, A.; Kern, W.; Beyer, J.; Pfutzner, A. Serum leptin is associated with serum uric acid concentrations in humans. Metabolism 1999, 48, 677–680. [CrossRef]
44. Matsuura, F.; Yamashita, S.; Nakamura, T.; Nishida, M.; Nozaki, S.; Funahashi, T.; Matsuzawa, Y. Effect of visceral fat accumulation on uric acid metabolism in male obese subjects: Visceral fat obesity is linked more closely to overproduction of uric acid than subcutaneous fat obesity. Metabolism 1998, 47, 929–933. [CrossRef]
45. Romao, I.; Roth, J. Genetic and environmental interactions in obesity and type 2 diabetes. J. Am. Diet. Assoc. 2008, 108 (4 Suppl. 1S), S24–S28. [CrossRef] [PubMed]
46. Choi, H.K.; Atkinson, K.; Karlson, E.W.; Willett, W.; Curhan, G. Purine-rich foods, dairy and protein intake, and the risk of gout in men. N. Engl. J. Med. 2004, 350, 1093–1103. [CrossRef] [PubMed]
47. Choi, J.W.; Ford, E.S.; Gao, X.; Choi, H.K. Sugar-sweetened soft drinks, diet soft drinks, and serum uric acid level: The Third National Health and Nutrition Examination Survey. Arthritis Rheum. 2008, 59, 109–116. [CrossRef] [PubMed]
48. Wang, Y.C.; Bleich, S.N.; Gortmaker, S.L. Increasing caloric contribution from sugar-sweetened beverages and 100% fruit juices among US children and adolescents, 1988–2004. Pediatrics 2008, 121, e1604–e1614. [CrossRef] [PubMed]
49. Wang, Y.M.; van Eys, J. Nutritional significance of fructose and sugar alcohols. Annu. Rev. Nutr. 1981, 1, 437–475. [CrossRef] [PubMed]
50. Hanover, L.M.; White, J.S. Manufacturing, composition, and applications of fructose. Am. J. Clin. Nutr. 1993, 58 (Suppl. S5), 724S–732S. [PubMed]
51. Lustig, R.H. Fructose: Metabolic, hedonic, and societal parallels with ethanol. J. Am. Diet. Assoc. 2010, 110, 1307–1321. [CrossRef] [PubMed]
52. Guilbaud, A.; Niquet-Leridon, C.; Boulanger, E.; Tessier, F.J. How Can Diet Affect the Accumulation of Advanced Glycation End-Products in the Human Body? Foods 2016, 5, 84. [CrossRef] [PubMed]
53. Bunn, H.F.; Higgins, P.J. Reaction of monosaccharides with proteins: Possible evolutionary significance. Science 1981, 213, 222–224. [CrossRef] [PubMed]
54. Suarez, G.; Rajaram, R.; Oronsky, A.L.; Gawinowicz, M.A. Nonenzymatic glycation of bovine serum albumin by fructose (fructation). Comparison with the Maillard reaction initiated by glucose. J. Biol. Chem. 1989, 264, 3674–3679. [PubMed]
55. Hallfrisch, J. Metabolic effects of dietary fructose. FASEB J. 1990, 4, 2652–2660. [PubMed]
56. Kaneko, C.; Ogura, J.; Sasaki, S.; Okamoto, K.; Kobayashi, M.; Kuwayama, K.; Narumi, K.; Iseki, K. Fructose suppresses uric acid excretion to the intestinal lumen as a result of the induction of oxidative stress by NADPH oxidase activation. Biochim. Biophys. Acta 2017, 1861, 559–566. [CrossRef] [PubMed]
57. Johnson, R.J.; Nakagawa, T.; Sanchez-Lozada, L.G.; Shafiu, M.; Sundaram, S.; Le, M.; Ishimoto, T.; Sautin, Y.Y.; Lanaspa, M.A. Sugar, uric acid, and the etiology of diabetes and obesity. Diabetes 2013, 62, 3307–3315. [CrossRef] [PubMed]
58. Van den Berghe, G.; Bronfman, M.; Vanneste, R.; Hers, H.G. The mechanism of adenosine triphosphate depletion in the liver after a load of fructose. A kinetic study of liver adenylate deaminase. Biochem. J. 1977, 162, 601–609. [CrossRef] [PubMed]
59. De Oliveira, E.P.; Burini, R.C. High plasma uric acid concentration: Causes and consequences. Diabetol. Metab. Syndr. 2012, 4, 12. [CrossRef] [PubMed]
60. Brosh, S.; Boer, P.; Sperling, O. Effects of fructose on synthesis and degradation of purine nucleotides in isolated rat hepatocytes. Biochim. Biophys. Acta 1982, 717, 459–464. [CrossRef]
61. Emmerson, B.T. Effect of oral fructose on urate production. Ann. Rheum. Dis. 1974, 33, 276–280. [CrossRef] [PubMed]
62. Kuzkaya, N.; Weissmann, N.; Harrison, D.G.; Dikalov, S. Interactions of peroxynitrite with uric acid in the presence of ascorbate and thiols: Implications for uncoupling endothelial nitric oxide synthase. Biochem. Pharmacol. 2005, 70, 343–354. [CrossRef] [PubMed]
63. Robinson, K.M.; Morre, J.T.; Beckman, J.S. Triuret: A novel product of peroxynitrite-mediated oxidation of urate. Arch Biochem. Biophys. 2004, 423, 213–217. [CrossRef] [PubMed]
64. Holme, I.; Aastveit, A.H.; Hammar, N.; Jungner, I.; Walldius, G. Uric acid and risk of myocardial infarction, stroke and congestive heart failure in 417,734 men and women in the Apolipoprotein MOrtality RISk study (AMORIS). J. Intern. Med. 2009, 266, 558–570. [CrossRef] [PubMed]
65. Kang, D.H.; Park, S.K.; Lee, I.K.; Johnson, R.J. Uric acid-induced C-reactive protein expression: Implication on cell proliferation and nitric oxide production of human vascular cells. J. Am. Soc. Nephrol. 2005, 16, 3553–3562. [CrossRef] [PubMed]
66. Yu, M.A.; Sanchez-Lozada, L.G.; Johnson, R.J.; Kang, D.H. Oxidative stress with an activation of the renin-angiotensin system in human vascular endothelial cells as a novel mechanism of uric acid-induced endothelial dysfunction. J. Hypertens. 2010, 28, 1234–1242. [CrossRef] [PubMed]
67. Sautin, Y.Y.; Nakagawa, T.; Zharikov, S.; Johnson, R.J. Adverse effects of the classic antioxidant uric acid in adipocytes: NADPH oxidase-mediated oxidative/nitrosative stress. Am. J. Physiol. Cell Physiol. 2007, 293, C584–C596. [CrossRef] [PubMed]
68. Verzola, D.; Ratto, E.; Villaggio, B.; Parodi, E.L.; Pontremoli, R.; Garibotto, G.; Viazzi, F. Uric acid promotes apoptosis in human proximal tubule cells by oxidative stress and the activation of NADPH oxidase NOX 4. PLoS ONE 2014, 9, e115210. [CrossRef] [PubMed]
69. De Souto Padron, F.A.; Salmon, A.B.; Bruno, F.; Jimenez, F.; Martinez, H.G.; Halade, G.V.; Ahuja, S.S.; Clark, R.A.; DeFronzo, R.A.; Abboud, H.E.; et al. Nox2 mediates skeletal muscle insulin resistance induced by a high fat diet. J. Biol. Chem. 2015, 290, 13427–13439. [CrossRef] [PubMed]
70. Streeter, J.; Thiel, W.; Brieger, K.; Miller, F.J., Jr. Opportunity nox: The future of NADPH oxidases as therapeutic targets in cardiovascular disease. Cardiovasc. Ther. 2013, 31, 125–137. [CrossRef] [PubMed]
71. Kanellis, J.; Kang, D.H. Uric acid as a mediator of endothelial dysfunction, inflammation, and vascular disease. Semin. Nephrol. 2005, 25, 39–42. [CrossRef] [PubMed]
72. Prata, C.; Grasso, C.; Loizzo, S.; Vieceli Dalla Sega, F.; Caliceti, C.; Zambonin, L.; Fiorentini, D.; Hakim, G.; Berridge, M.V.; Landi, L. Inhibition of trans-plasma membrane electron transport: A potential anti-leukemic strategy. Leuk. Res. 2010, 34, 1630–1635. [CrossRef] [PubMed]
73. Sodhi, K.; Hilgefort, J.; Banks, G.; Gilliam, C.; Stevens, S.; Ansinelli, H.A.; Getty, M.; Abraham, N.G.; Shapiro, J.I.; Khitan, Z. Uric Acid-Induced Adipocyte Dysfunction Is Attenuated by HO-1 Upregulation: Potential Role of Antioxidant Therapy to Target Obesity. Stem Cells Int. 2016, 2016, 8197325. [CrossRef] [PubMed]
74. Landmesser, U.; Spiekermann, S.; Preuss, C.; Sorrentino, S.; Fischer, D.; Manes, C.; Mueller, M.; Drexler, H. Angiotensin II induces endothelial xanthine oxidase activation: Role for endothelial dysfunction in patients with coronary disease. Arterioscler. Thromb. Vasc. Biol. 2007, 27, 943–948. [CrossRef] [PubMed]
75. Baldus, S.; Koster, R.; Chumley, P.; Heitzer, T.; Rudolph, V.; Ostad, M.A.; Warnholtz, A.; Staude, H.J.; Thuneke, F.; Koss, K.; et al. Oxypurinol improves coronary and peripheral endothelial function in patients with coronary artery disease. Free Radic. Biol. Med. 2005, 39, 1184–1190. [CrossRef] [PubMed]
76. Price, K.L.; Sautin, Y.Y.; Long, D.A.; Zhang, L.; Miyazaki, H.; Mu, W.; Endou, H.; Johnson, R.J. Human vascular smooth muscle cells express a urate transporter. J. Am. Soc. Nephrol. 2006, 17, 1791–1795. [CrossRef] [PubMed]
77. Sugihara, S.; Hisatome, I.; Kuwabara, M.; Niwa, K.; Maharani, N.; Kato, M.; Ogino, K.; Hamada, T.; Ninomiya, H.; Higashi, Y.; et al. Depletion of Uric Acid Due to SLC22A12 (URAT1) Loss-of-Function Mutation Causes Endothelial Dysfunction in Hypouricemia. Circ. J. 2015, 79, 1125–1132. [CrossRef] [PubMed]
78. Liang, W.Y.; Zhu, X.Y.; Zhang, J.W.; Feng, X.R.; Wang, Y.C.; Liu, M.L. Uric acid promotes chemokine and adhesion molecule production in vascular endothelium via nuclear factor-kappa B signaling. Nutr. Metab. Cardiovasc. Dis. 2015, 25, 187–194. [CrossRef] [PubMed]
79. Schmitz, B.; Brand, S.M. Uric acid and essential hypertension: The endothelial connection. J. Hypertens. 2016, 34, 2138–2139. [CrossRef] [PubMed]
80. Puddu, P.; Puddu, G.M.; Cravero, E.; Vizioli, L.; Muscari, A. Relationships among hyperuricemia, endothelial dysfunction and cardiovascular disease: Molecular mechanisms and clinical implications. J. Cardiol. 2012, 59, 235–242. [CrossRef] [PubMed]
81. Godber, B.L.; Doel, J.J.; Sapkota, G.P.; Blake, D.R.; Stevens, C.R.; Eisenthal, R.; Harrison, R. Reduction of nitrite to nitric oxide catalyzed by xanthine oxidoreductase. J. Biol. Chem. 2000, 275, 7757–7763. [CrossRef] [PubMed]
82. Li, H.; Samouilov, A.; Liu, X.; Zweier, J.L. Characterization of the magnitude and kinetics of xanthine oxidase-catalyzed nitrate reduction: Evaluation of its role in nitrite and nitric oxide generation in anoxic tissues. Biochemistry 2003, 42, 1150–1159. [CrossRef] [PubMed]
83. Millar, T.M.; Stevens, C.R.; Benjamin, N.; Eisenthal, R.; Harrison, R.; Blake, D.R. Xanthine oxidoreductase catalyses the reduction of nitrates and nitrite to nitric oxide under hypoxic conditions. FEBS Lett. 1998, 427, 225–228. [CrossRef]
84. Hink, H.U.; Santanam, N.; Dikalov, S.; McCann, L.; Nguyen, A.D.; Parthasarathy, S.; Harrison, D.G.; Fukai, T. Peroxidase properties of extracellular superoxide dismutase: Role of uric acid in modulating in vivo activity. Arterioscler. Thromb. Vasc. Biol. 2002, 22, 1402–1408. [CrossRef] [PubMed]
85. Nozik-Grayck, E.; Suliman, H.B.; Piantadosi, C.A. Extracellular superoxide dismutase. Int. J. Biochem. Cell Biol. 2005, 37, 2466–2471. [CrossRef] [PubMed]
86. Nieto, F.J.; Iribarren, C.; Gross, M.D.; Comstock, G.W.; Cutler, R.G. Uric acid and serum antioxidant capacity: A reaction to atherosclerosis? Atherosclerosis 2000, 148, 131–139. [CrossRef]
87. Suzuki, T. Nitrosation of uric acid induced by nitric oxide under aerobic conditions. Nitric Oxide 2007, 16, 266–273. [CrossRef] [PubMed]
88. Khanna, D.; Fitzgerald, J.D.; Khanna, P.P.; Bae, S.; Singh, M.K.; Neogi, T.; Pillinger, M.H.; Merill, J.; Lee, S.; Prakash, S.; et al. 2012 American College of Rheumatology guidelines for management of gout. Part 1: Systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res. (Hoboken) 2012, 64, 1431–1446. [CrossRef] [PubMed]
89. Feig, D.I.; Soletsky, B.; Johnson, R.J. Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: A randomized trial. JAMA 2008, 300, 924–932. [CrossRef] [PubMed]
90. Zhu, Y.; Pandya, B.J.; Choi, H.K. Prevalence of gout and hyperuricemia in the US general population: The National Health and Nutrition Examination Survey 2007–2008. Arthritis Rheum. 2011, 63, 3136–3141. [CrossRef] [PubMed]
91. Cox, C.L.; Stanhope, K.L.; Schwarz, J.M.; Graham, J.L.; Hatcher, B.; Griffen, S.C.; Bremer, A.A.; Berglund, L.; McGahan, J.P.; Keim, N.L.; et al. Consumption of fructose- but not glucose-sweetened beverages for 10 weeks increases circulating concentrations of uric acid, retinol binding protein-4, and gamma-glutamyl transferase activity in overweight/obese humans. Nutr. Metab. 2012, 9, 68. [CrossRef] [PubMed]
92. Abdelmalek, M.F.; Lazo, M.; Horska, A.; Bonekamp, S.; Lipkin, E.W.; Balasubramanyam, A.; Bantle, J.P.; Johnson, R.J.; Diehl, A.M.; Clark, J.M. Higher dietary fructose is associated with impaired hepatic adenosine triphosphate homeostasis in obese individuals with type 2 diabetes. Hepatology 2012, 56, 952–960. [CrossRef] [PubMed]
93. Hu, Q.H.; Wang, C.; Li, J.M.; Zhang, D.M.; Kong, L.D. Allopurinol, rutin, and quercetin attenuate hyperuricemia and renal dysfunction in rats induced by fructose intake: Renal organic ion transporter involvement. Am. J. Physiol. Renal. Physiol. 2009, 297, F1080–F1091. [CrossRef] [PubMed]
94. Wang, D.D.; Sievenpiper, J.L.; de Souza, R.J.; Chiavaroli, L.; Ha, V.; Cozma, A.I.; Mirrahimi, A.; Yu, M.E.; Carleton, A.J.; Di Buono, M.; et al. The effects of fructose intake on serum uric acid vary among controlled dietary trials. J. Nutr. 2012, 142, 916–923. [CrossRef] [PubMed]
95. Bruun, J.M.; Maersk, M.; Belza, A.; Astrup, A.; Richelsen, B. Consumption of sucrose-sweetened soft drinks increases plasma levels of uric acid in overweight and obese subjects: A 6-month randomised controlled trial. Eur. J. Clin. Nutr. 2015, 69, 949–953. [CrossRef] [PubMed]
96. Stanhope, K.L.; Medici, V.; Bremer, A.A.; Lee, V.; Lam, H.D.; Nunez, M.V.; Chen, G.X.; Keim, N.L.; Havel, P.J. A dose-response study of consuming high-fructose corn syrup-sweetened beverages on lipid/lipoprotein risk factors for cardiovascular disease in young adults. Am. J. Clin. Nutr. 2015, 101, 1144–1154. [CrossRef] [PubMed]
97. Le, M.T.; Frye, R.F.; Rivard, C.J.; Cheng, J.; McFann, K.K.; Segal, M.S.; Johnson, R.J.; Johnson, J.A. Effects of high-fructose corn syrup and sucrose on the pharmacokinetics of fructose and acute metabolic and hemodynamic responses in healthy subjects. Metabolism 2012, 61, 641–651. [CrossRef] [PubMed]
98. Madero, M.; Rodríguez Castellanos, F.E.; Jalal, D.; Villalobos-Martín, M.; Salazar, J.; Vazquez-Rangel, A.; Johnson, R.J.; Sanchez-Lozada, L.G. A pilot study on the impact of a low fructose diet and allopurinol on clinic blood pressure among overweight and prehypertensive subjects: A randomized placebo controlled trial. J. Am. Soc. Hypertens. 2015, 9, 837–844. [CrossRef] [PubMed]
99. Moriarity, J.T.; Folsom, A.R.; Iribarren, C.; Nieto, F.J.; Rosamond, W.D. Serum uric acid and risk of coronary heart disease: Atherosclerosis Risk in Communities (ARIC) Study. Ann. Epidemiol. 2000, 10, 136–143. [CrossRef]
100. Sakata, K.; Hashimoto, T.; Ueshima, H.; Okayama, A. Absence of an association between serum uric acid and mortality from cardiovascular disease: NIPPON DATA 80, 1980–1994. National Integrated Projects for Prospective Observation of Non-communicable Diseases and its Trend in the Aged. Eur. J. Epidemiol. 2001, 17, 461–468. [CrossRef] [PubMed]
101. Wannamethee, S.G.; Shaper, A.G.; Whincup, P.H. Serum urate and the risk of major coronary heart disease events. Heart 1997, 78, 147–153. [CrossRef] [PubMed]
102. Wheeler, J.G.; Juzwishin, K.D.; Eiriksdottir, G.; Gudnason, V.; Danesh, J. Serum uric acid and coronary heart disease in 9,458 incident cases and 155,084 controls: Prospective study and meta-analysis. PLoS Med. 2005, 2, e76. [CrossRef] [PubMed]
103. Abbott, R.D.; Brand, F.N.; Kannel, W.B.; Castelli, W.P. Gout and coronary heart disease: The Framingham Study. J. Clin. Epidemiol. 1988, 41, 237–242. [CrossRef]
104. Waring, W.S.; Webb, D.J.; Maxwell, S.R. Uric acid as a risk factor for cardiovascular disease. QJM 2000, 93, 707–713. [CrossRef] [PubMed]
105. Pillinger, M.H.; Goldfarb, D.S.; Keenan, R.T. Gout and its comorbidities. Bull. NYU Hosp. Jt. Dis. 2010, 68, 199–203. [PubMed]
106. Jayalath, V.H.; Sievenpiper, J.L.; de Souza, R.J.; Ha, V.; Mirrahimi, A.; Santaren, I.D.; Blanco, M.S.; Di, B.M.; Jenkins, A.L.; Leiter, L.A.; et al. Total fructose intake and risk of hypertension: A systematic review and meta-analysis of prospective cohorts. J. Am. Coll. Nutr. 2014, 33, 328–339. [CrossRef] [PubMed]
107. Jayalath, V.H.; de Souza, R.J.; Ha, V.; Mirrahimi, A.; Blanco-Mejia, S.; Di, B.M.; Jenkins, A.L.; Leiter, L.A.; Wolever, T.M.; Beyene, J.; et al. Sugar-sweetened beverage consumption and incident hypertension: A systematic review and meta-analysis of prospective cohorts. Am. J. Clin. Nutr. 2015, 102, 914–921. [CrossRef] [PubMed]
108. Cicero, A.F.; Dormi, A.; D’Addato, S.; Gaddi, A.V.; Borghi, C. Long-term effect of a dietary education program on postmenopausal cardiovascular risk and metabolic syndrome: The Brisighella Heart Study. J. Womens Health 2010, 19, 133–137. [CrossRef] [PubMed]
109. Cicero, A.F.; Rosticci, M.; Bove, M.; Fogacci, F.; Giovannini, M.; Urso, R.; D’Addato, S.; Borghi, C. Serum uric acid change and modification of blood pressure and fasting plasma glucose in an overall healthy population sample: Data from the Brisighella heart study. Ann. Med. 2017, 49, 275–282. [CrossRef] [PubMed]
110. Cicero, A.F.; Rosticci, M.; Cagnati, M.; Urso, R.; Scapagnini, G.; Morbini, M.; Grandi, E.; D’Addato, S.; Borghi, C. Serum uric acid and markers of low-density lipoprotein oxidation in nonsmoking healthy subjects: Data from the Brisighella Heart Study. Pol. Arch. Med. Wewn. 2014, 124, 661–668. [PubMed]
111. Cicero, A.F.; Rosticci, M.; Fogacci, F.; Grandi, E.; D’Addato, S.; Borghi, C. High serum uric acid is associated to poorly controlled blood pressure and higher arterial stiffness in hypertensive subjects. Eur. J. Intern. Med. 2017, 37, 38–42. [CrossRef] [PubMed]
112. Cicero, A.F.; Desideri, G.; Grossi, G.; Urso, R.; Rosticci, M.; D’Addato, S.; Borghi, C. Serum uric acid and impaired cognitive function in a cohort of healthy young elderly: Data from the Brisighella Study. Intern. Emerg Med. 2015, 10, 25–31. [CrossRef] [PubMed]
113. Cicero, A.F.; Rosticci, M.; Parini, A.; Baronio, C.; D’Addato, S.; Borghi, C. Serum uric acid is inversely proportional to estimated stroke volume and cardiac output in a large sample of pharmacologically untreated subjects: Data from the Brisighella Heart Study. Intern. Emerg Med. 2014, 9, 655–660. [CrossRef] [PubMed]
114. Sun, S.Z.; Anderson, G.H.; Flickinger, B.D.; Williamson-Hughes, P.S.; Empie, M.W. Fructose and non-fructose sugar intakes in the US population and their associations with indicators of metabolic syndrome. Food Chem. Toxicol. 2011, 49, 2875–2882. [CrossRef] [PubMed]
115. Okafor, O.N.; Farrington, K.; Gorog, D.A. Allopurinol as a therapeutic option in cardiovascular disease. Pharmacol. Ther. 2016, 172, 139–150. [CrossRef] [PubMed]
116. Wu, A.H.; Ghali, J.K.; Neuberg, G.W.; O’Connor, C.M.; Carson, P.E.; Levy, W.C. Uric acid level and allopurinol use as risk markers of mortality and morbidity in systolic heart failure. Am. Heart J. 2010, 160, 928–933. [CrossRef] [PubMed]
117. Baldus, S.; Mullerleile, K.; Chumley, P.; Steven, D.; Rudolph, V.; Lund, G.K.; Staude, H.J.; Stork, A.; Koster, R.; Kahler, J.; et al. Inhibition of xanthine oxidase improves myocardial contractility in patients with ischemic cardiomyopathy. Free Radic. Biol. Med. 2006, 41, 1282–1288. [CrossRef] [PubMed]
118. Ogino, K.; Kato, M.; Furuse, Y.; Kinugasa, Y.; Ishida, K.; Osaki, S.; Kinugawa, T.; Igawa, O.; Hisatome, I.; Shigemasa, C.; et al. Uric acid-lowering treatment with benzbromarone in patients with heart failure: A double-blind placebo-controlled crossover preliminary study. Circ. Heart Fail. 2010, 3, 73–81. [CrossRef] [PubMed]
119. Iribarren, C.; Folsom, A.R.; Eckfeldt, J.H.; McGovern, P.G.; Nieto, F.J. Correlates of uric acid and its association with asymptomatic carotid atherosclerosis: The ARIC Study. Atherosclerosis Risk in Communities. Ann. Epidemiol. 1996, 6, 331–340. [CrossRef]
120. Johnson, R.J.; Kang, D.H.; Feig, D.; Kivlighn, S.; Kanellis, J.; Watanabe, S.; Tuttle, K.R.; Rodriguez-Iturbe, B.; Herrera-Acosta, J.; Mazzali, M. Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease? Hypertension 2003, 41, 1183–1190. [CrossRef] [PubMed]
121. Borghi, C.; Cicero, A.F. Serum Uric Acid and Cardiometabolic Disease: Another Brick in the Wall? Hypertension 2017. [CrossRef] [PubMed]
122. Bove, M.; Cicero, A.F.; Veronesi, M.; Borghi, C. An evidence-based review on urate-lowering treatments: Implications for optimal treatment of chronic hyperuricemia. Vasc. Health Risk Manag. 2017, 13, 23–28. [CrossRef] [PubMed]
123. Caliceti, C.; Calabria, D.; Roda, A. A new sensitive and quantitative chemiluminescent assay to monitor intracellular xanthine oxidase activity for rapid screening of inhibitors in living endothelial cells. Anal. Bioanal. Chem. 2016, 408, 8755–8760. [CrossRef] [PubMed]